**Ventilator-Associated Event (VAE)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 1 of 4 | | | | | | | \*required for saving \*\*required for completion | | | | |
| Facility ID: | | | | | Event #: | | | | | | |
| \*Patient ID: | | | | | Social Security #: | | | | | | |
| Secondary ID: | | | | | Medicare #: | | | | | | |
| Patient Name, Last: | | | | | First: | | | | | Middle: | |
| \*Gender: F M Other | | | | | \*Date of Birth: | | | | | | |
| Ethnicity (Specify): | | | | | Race (Specify): | | | | | | |
| \*Event Type: VAE | | | | | \*Date of Event: | | | | | | |
| Post-procedure VAE: Yes No | | | | | Date of Procedure: | | | | | | |
| NHSN Procedure Code: | | | | | ICD-9-CM Procedure Code: | | | | | | |
| \*MDRO Infection Surveillance: | | | | | | | | | | | |
| □ Yes, this infection’s pathogen & location are in-plan for Infection Surveillance in the MDRO/CDI Module | | | | | | | | | | | |
| □ No, this infection’s pathogen & location are **not** in-plan for Infection Surveillance in the MDRO/CDI Module | | | | | | | | | | | |
| \*Date Admitted to Facility: | | | | | \*Location: | | | | | | |
| \* Location of Mechanical Ventilation Initiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | | | \*Date Initiated: \_\_ /\_\_ /\_\_\_\_\_ | | \*APRV: Yes No |
| **Event Details** | | | | | | | | | | | |
| \*Specific Event: | □ VAC | □ IVAC | | □ Possible VAP | | | | □ Probable VAP | | | |
| \*Specify Criteria Used: | | | | | | | | | | | |
| STEP 1: VAC (≥1 REQUIRED) | | | | | | | | | | | |
| □ Daily min FiO2 increase ≥ 0.20 (20 points) for ≥ 2 days† | | | | | | **OR** □ Daily min PEEP increase ≥ 3 cm H2O for ≥ 2 days† | | | | | |
| †*after 2+ days of stable or decreasing daily minimum values.* | | | | | | | | | | | |
| STEP 2: IVAC | | | | | | | | | | | |
| □ Temperature > 38°C or < 36° **OR** □ White blood cell count ≥ 12,000 or ≤ 4,000 cells/mm3 | | | | | | | | | | | |
| **AND** | | | | | | | | | | | |
| □ A new antimicrobial agent(s) is started, and is continued for ≥ 4 days | | | | | | | | | | | |
| STEP 3: Possible VAP | | | | | | | STEP 3: Probable VAP | | | | |
| □ Purulent respiratory secretions‡ (defined as secretions from the lungs, bronchi, or trachea that contain >25 neutrophils and <10 squamous epithelial cells per low power field [lpf, x100], or equivalent semi-quantitative results) | | | | | | | □ Purulent respiratory secretions‡  **AND** one of the following (meeting quantitative or semi- quantitative threshold as outlined in protocol):‡  □ Positive culture of endotracheal aspirate  □ Positive culture of bronchoalveolar lavage  □ Positive culture of lung tissue  □ Positive culture of protected specimen brushing  **OR**  □ One of the following results(without requirement for purulent respiratory secretions), as outlined in protocol:‡  □ Positive pleural fluid culture  □ Positive lung histopathology  □ Positive diagnostic test for Legionella spp.  □ Positive diagnostic test for viral pathogens | | | | |
| **OR**  □ One of the following (qualitative, semi-quantitative or quantitative):‡  □ Positive culture of sputum  □ Positive culture of endotracheal aspirate  □ Positive culture of bronchoalveolar lavage  □ Positive culture of lung tissue  □ Positive culture of protected specimen brushing | | | | | | |
| ‡*collected after 2 days of mechanical ventilation and within +/- 2 days of onset of increase in FiO2 or PEEP.* | | | | | | | | | | | |
| \*Secondary Bloodstream Infection: Yes No | | | | | | | | | | | |
| \*\*Died: Yes No | | | VAE Contributed to Death: Yes No | | | | | | | | |
| Discharge Date: | | | \*Pathogens Identified: Yes No \*If Yes, specify on pages 2-3 | | | | | | | | |
| Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).  Public reporting burden of this collection of information is estimated to average 22 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).  CDC 57.112 (Front), Rev 2 v8.0 | | | | | | | | | | | |

**Ventilator-Associated Event (VAE)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 2 of 4 | | | | | | | | | | |
| Pathogen # | **Gram-positive Organisms** | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Staphylococcus* coagulase-negative | | | **VANC**  S I R N | | | | | | |
| (specify species if available):  \_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | | | |
| \_\_\_\_\_\_\_ | *\_\_\_\_Enterococcus faecium*  *\_\_\_\_Enterococcus faecalis*    *\_\_\_\_Enterococcus* spp.  (Only those not identified to the species level) | | | **DAPTO**  S NS N | **GENTHL§**  S R N | | **LNZ**  S I R N | **VANC**  S I R N |  | |
| \_\_\_\_\_\_\_ | *Staphylococcus aureus* | **CIPRO/LEVO/MOXI**  S I R N | | **CLIND**  S I R N | **DAPTO**  S NS N | **DOXY/MINO**  S I R N | | **ERYTH**  S I R N | **GENT**  S I R N | **LNZ**  S R N |
| **OX/CEFOX/METH**  S I R N | | **RIF**  S I R N | **TETRA**  S I R N | **TIG**  S NS N | | **TMZ**  S I R N | **VANC**  S I R N |  |
| Pathogen # | **Gram-negative Organisms** | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Acinetobacter*  (specify species)  \_\_\_\_\_\_\_\_\_\_\_\_ | **AMK**  S I R N | **AMPSUL**  S I R N | **AZT**  S I R N | **CEFEP**  S I R N | **CEFTAZ**  S I R N | | **CIPRO/LEVO**  S I R N | | **COL/PB**  S I R N |
| **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | **PIP/PIPTAZ**  S I R N | | | **TETRA/DOXY/MINO**  S I R N | |
| **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | | |
| \_\_\_\_\_\_\_ | *Escherichia coli* | **AMK**  S I R N | **AMP**  S I R N | **AMPSUL/AMXCLV**  S I R N | | **AZT**  S I R N | | **CEFAZ**  S I R N | **CEFEP**  S I R N | **CEFOT/CEFTRX**  S I R N |
| **CEFTAZ**  S I R N | **CEFUR**  S I R N | **CEFOX/CETET**  S I R N | | **CIPRO/LEVO/MOXI**  S I R N | | | **COL/PB†**  S R N | |
| **ERTA**  S I R N | **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | | **PIPTAZ**  S I R N | **TETRA/DOXY/MINO**  S I R N | |
| **TIG**  S I R N | **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | |
| \_\_\_\_\_\_\_ | *Enterobacter*  (specify species)  \_\_\_\_\_\_\_\_\_\_\_\_ | **AMK**  S I R N | **AMP**  S I R N | **AMPSUL/AMXCLV**  S I R N | | **AZT**  S I R N | | **CEFAZ**  S I R N | **CEFEP**  S I R N | **CEFOT/CEFTRX**  S I R N |
| **CEFTAZ**  S I R N | **CEFUR**  S I R N | **CEFOX/CETET**  S I R N | | **CIPRO/LEVO/MOXI**  S I R N | | | **COL/PB†**  S R N | |
| **ERTA**  S I R N | **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | | **PIPTAZ**  S I R N | **TETRA/DOXY/MINO**  S I R N | |
| **TIG**  S I R N | **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | |
| \_\_\_\_\_\_\_ | *\_\_\_\_Klebsiella*  *pneumonia*  *\_\_\_\_Klebsiella*  *oxytoca* | **AMK**  S I R N | **AMP**  S I R N | **AMPSUL/AMXCLV**  S I R N | | **AZT**  S I R N | | **CEFAZ**  S I R N | **CEFEP**  S I R N | **CEFOT/CEFTRX**  S I R N |
| **CEFTAZ**  S I R N | **CEFUR**  S I R N | **CEFOX/CETET**  S I R N | | **CIPRO/LEVO/MOXI**  S I R N | | | **COL/PB†**  S R N | |
| **ERTA**  S I R N | **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | | **PIPTAZ**  S I R N | **TETRA/DOXY/MINO**  S I R N | |
| **TIG**  S I R N | **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | |

**Ventilator-Associated Event (VAE)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 3 of 4 | | | | | | | | | | | | | | | | | | |
| Pathogen # | **Gram-negative Organisms (*continued*)** | | | | | | | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Pseudomonas aeruginosa* | **AMK**  S I R N | | | **AZT**  S I R N | **CEFEP**  S I R N | | **CEFTAZ**  S I R N | | | | **CIPRO/LEVO**  S I R N | | | **COL/PB**  S I R N | | **GENT**  S I R N | |
|  |  | **IMI**  S I R N | | | **MERO/DORI**  S I R N | | | **PIP/PIPTAZ**  S I R N | | | | **TOBRA**  S I R N | | | | | | |
| Pathogen # | **Fungal Organisms** | | | | | | | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Candida*  (specify species if available)  \_\_\_\_\_\_\_\_\_\_\_\_ | **ANID**  S I R N | **CASPO**  S NS N | | | **FLUCO**  S S-DD R N | | | | **FLUCY**  S I R N | | **ITRA**  S S-DD R N | | | **MICA**  S NS N | | **VORI**  S S-DD R N | |
| Pathogen # | **Other Organisms** | | | | | | | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | Organism 1 (specify)  \_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1  S I R N | | \_\_\_\_\_\_\_ Drug 2  S I R N | | | \_\_\_\_\_\_  Drug 3  S I R N | | \_\_\_\_\_\_\_ Drug 4  S I R N | | \_\_\_\_\_\_\_Drug 5  S I R N | | \_\_\_\_\_\_ Drug 6  S I R N | \_\_\_\_\_\_ Drug 7  S I R N | | \_\_\_\_\_\_ Drug 8  S I R N | | \_\_\_\_\_\_ Drug 9  S I R N |
| \_\_\_\_\_\_\_ | Organism 1 (specify)  \_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1  S I R N | | \_\_\_\_\_\_\_ Drug 2  S I R N | | | \_\_\_\_\_\_  Drug 3  S I R N | | \_\_\_\_\_\_\_ Drug 4  S I R N | | \_\_\_\_\_\_\_Drug 5  S I R N | | \_\_\_\_\_\_ Drug 6  S I R N | \_\_\_\_\_\_ Drug 7  S I R N | | \_\_\_\_\_\_ Drug 8  S I R N | | \_\_\_\_\_\_ Drug 9  S I R N |
| \_\_\_\_\_\_\_ | Organism 1 (specify)  \_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1  S I R N | | \_\_\_\_\_\_\_ Drug 2  S I R N | | | \_\_\_\_\_\_  Drug 3  S I R N | | \_\_\_\_\_\_\_ Drug 4  S I R N | | \_\_\_\_\_\_\_Drug 5  S I R N | | \_\_\_\_\_\_ Drug 6  S I R N | \_\_\_\_\_\_ Drug 7  S I R N | | \_\_\_\_\_\_ Drug 8  S I R N | | \_\_\_\_\_\_ Drug 9  S I R N |

**Result Codes**

**S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested**

**§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic**

**† Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4**

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug Codes:** |  |  |  |
| AMK = amikacin | CEFTRX = ceftriaxone | FLUCY = flucytosine | OX = oxacillin |
| AMP = ampicillin | CEFUR= cefuroxime | GENT = gentamicin | PB = polymyxin B |
| AMPSUL = ampicillin/sulbactam | CETET= cefotetan | GENTHL = gentamicin –high level test | PIP = piperacillin |
| AMXCLV = amoxicillin/clavulanic acid | CIPRO = ciprofloxacin | IMI = imipenem | PIPTAZ = piperacillin/tazobactam |
| ANID = anidulafungin | CLIND = clindamycin | ITRA = itraconazole | RIF = rifampin |
| AZT = aztreonam | COL = colistin | LEVO = levofloxacin | TETRA = tetracycline |
| CASPO = caspofungin | DAPTO = daptomycin | LNZ = linezolid | TIG = tigecycline |
| CEFAZ= cefazolin | DORI = doripenem | MERO = meropenem | TMZ = trimethoprim/sulfamethoxazole |
| CEFEP = cefepime | DOXY = doxycycline | METH = methicillin | TOBRA = tobramycin |
| CEFOT = cefotaxime | ERTA = ertapenem | MICA = micafungin | VANC = vancomycin |
| CEFOX= cefoxitin | ERYTH = erythromycin | MINO = minocycline | VORI = voriconazole |
| CEFTAZ = ceftazidime | FLUCO = fluconazole | MOXI = moxifloxacin |  |

**Ventilator-Associated Event (VAE)**

|  |  |  |  |
| --- | --- | --- | --- |
| Page 4 of 4 | | | |
| **Custom Fields** | | | |
| Label | | Label | |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_/\_\_\_\_/\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_/\_\_\_\_/\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Comments** | | | |
|  | | | |